middle.news
Argent BioPharma Cuts US$5.5m Debt with Splash Licensing Deal, Advances Veterinary Assets
8:25am on Tuesday 28th of July, 2026 AEST
•
Biotechnology
Read Story
Argent BioPharma Cuts US$5.5m Debt with Splash Licensing Deal, Advances Veterinary Assets
8:25am on Tuesday 28th of July, 2026 AEST
Key Points
US$5.5 million secured debt forgiven via Splash Beverage licensing deal
Acquisition of 48% interest in CannPal Animal Therapeutics finalised
Positive Phase 2C results advance veterinary CPAT-01 towards Phase 3
Operating cash outflows of A$600,000 with closing cash at A$141,000
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argent Biopharma (ASX:RGT)
OPEN ARTICLE